News

Piper Sandler Sticks to Its Hold Rating for Biogen (BIIB)
In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...
EU authorizes Eisai-Biogen's drug for early Alzheimer's treatment
The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...
Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag
Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...
Biogen reports EC grants marketing authorization for Leqembi
The European Commission has granted the amyloid-beta monoclonal antibody Leqembi Marketing Authorization in the European Union. Lecanemab is ...
Yahoo Finance5d
Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?
Biogen Inc. (BIIB) shares rallied 5.7% in the last trading session to close at $120.49. This move can be attributable to notable volume with a higher number of shares being traded than in a ...
Biogen Inc. stock underperforms Thursday when compared to competitors
Shares of Biogen Inc. BIIB slipped 5.90% to $113.38 Thursday, on what proved to be an all-around rough trading session for ...
Biogen Inc. (NASDAQ:BIIB) Receives Average Rating of “Hold” from Analysts
Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are ...
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild ...